Jump to content

Hospital Quirónsalud Valencia
  • Contact us
  • Site map
  • IntranetLink to external application.
  • Twitter This link will open in a pop-up window.
  • Facebook This link will open in a pop-up window.
  • Youtube This link will open in a pop-up window.
  • Linkedin This link will open in a pop-up window.
  • Instagram This link will open in a pop-up window.
  • Book an appointment
  • My Quirónsalud This link will open in a pop-up window.
Language selector
Active language English
  • español
  • English
  • International version
    • Español
    • English
    • Deutsch
    • Pусский
    • Italiano
Location and transport
963 69 06 00
  • Our hospital
    • Why choose our hospital?
    • Contact information
    • Schedule
    • Facilities and services
    • Technology
    • Location and transport
    • Photo gallery and multimedia
  • Medical team
  • Services
  • Join us This link will open in a pop-up window.
  • Insurance companies
  • News
    • NoticiasLatest news
    • Events calendar
    • Photo gallery and multimedia
  • Special offers
  • Patients and Visitors
  • Professionals
  • Research
  • Learn with us
  • Home
  •   |   Research
  •   |   Clinical trials
  •   |   Hepatology
  • Tweet
  • Share on Facebook
  • Share on Linkedin
  • Share on WhatsApp

Hepatology

  • Phase III, open-label, single-group study to evaluate the safety and efficacy of TMC435 plus pegylated interferon alfa-2a and ribavirin administered for 12 weeks in untreated subjects with chronic HCV infection of genotype 1 '
  • Follow-up study to evaluate the resistance and durability of the response to treatment with AbbVie direct-acting anitivirals (ADA) in subjects who participated in phase 2 or phase 3 clinical trials for the treatment of chronic hepatitis C virus infection
  • Phase 3, randomized, open and controlled study of a non-interferon regimen with active ingredient BI 207127 in combination with Fladaprevir and Ribavirin, compared to Telaprevir in combination with pegylated interferon alpha and ribavirin for the treatment of chronic hepatitis virus infection C (HCV) genotype 1b in patients without previous treatment
  • Phase 2 study, open, of daclatasvir (BMS-790052) and TMC435 in combination with or without ribavirin (RBV), for the treatment of previously untreated subjects or subjects with no response to previous treatment with penginterferon alfa (peglFN) with hepatitis C chronic genotype 1
  • Retrospective observational study to describe the response to lead-in with peginterferon / ribavirin as a clinical decision tool in patients treated with Vietrelis (boceprevir)
  • A randomized, double-blind, controlled study to evaluate the efficacy and safety of the combination ABT-450 / ritonavir / ABT-267 (ABT-450 / r / ABT267) and ABT-333 with and without ribavirin (RBV) in adults with chronic infection with Hepatitis C virus genotype 1b, not previously treated (PEARL-III)
  • Comparative Assessement of effectiveness of antiviral therapies in Hepatitis C (CMPASS)
  • Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT450 / ritonavir / ABT-267 and ABT-333 administered together with ribavirin (RBV) in adults with chronic infection with hepatitis C virus (HCV) ) of genotype1, previously treated (SAPPHIRE II)
  • Nested, retrospective, observational and non-interventional case-control study to evaluate the risk of thromboembolic events associated with surgery and eltrompag exposure in ENABLE studies
  • Randomized, open, multicenter study to evaluate the antiviral activity, safety and pharmacokinetics of ABT-450, with ritonavir (ABT-450 / r) in combination with ABT-267 and / or ABT-333, with or without ribavirin ( RBV), for 8, 12 or 24 weeks to patients with chronic hepatitis C virus genotype 1 infection who have not received prior treatment or no responders
14 results
Pages: 1 2 next >
Research
  • Clinical trials
  • Portal del paciente
  • Tu canal de salud - Noticias y consejos de salud
  • Nuestros blogs
  • Test genéticos para la prevención de enfermedades
banner quironsalud gris
Location and transport

Hospital Quirónsalud Valencia

Avda. Blasco Ibáñez, 14
46010 Valencia Valencia

963 69 06 00
  • Legal notice
  • Privacy and data protection
  • Cookies policy
  • Accessibility
  • Contact us
  • Site map
  • IntranetLink to external application.
  • Twitter This link will open in a pop-up window.
  • Facebook This link will open in a pop-up window.
  • Youtube This link will open in a pop-up window.
  • Linkedin This link will open in a pop-up window.
  • Instagram This link will open in a pop-up window.
© 2018 Quirónsalud - All rights reserved